Views
4 years ago

30 - SA Alvano - Febrero 2005

  • Text
  • Litio
  • Diferentes
  • Mecanismos
  • Trastorno
  • Efecto
  • Bipolar
  • Quinasa
  • Tratamiento
  • Mecanismo
  • Valproato
Posibles mecanismos y acciones farmacológicas involucradas en el efecto antimaníaco y estabilizador del humor (Primera parte)

Sebastián Alejandro

Sebastián Alejandro Alvano Referencias bibliográficas 1) Freeman MP, Wiegand Ch, Gelenberg AJ. Lithium. Schatzberg AF, Nemeroff ChB. Textbook of Psychopharmacology. 3 ed. Washington DC: American Psychiatric Publishing;2004. p. 547-65. 2) Alvano SA. Pautas para el tratamiento del trastorno bipolar. Zieher LM, Alvano SA, Fadel D, Iannantuno R, Serra A, editores. Psiconeurofarmacología clínica y sus bases neurocientíficas. 3 ed. Buenos Aires: Siltor;2003. p. 398- 403. 3) Lenox RH, Frazer A. Mechanism of action of antidepressants and mood stabilizers. Davis KL, Charney D, Coyle JT, Nemeroff ChB. Neuropsychopharmacology, the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins ;2002. p. 1139-63. 4) Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004;29:32-8. 5) Cordeiro ML, Gundersen CB, Umbach J. Convergente effects of lithium and valproate on the depression of proteins associated with large dense core vesicles in NGF-differentiated PCI2 cells. Neuropsychopharmacology 2004;29:39-44. 6) Mc Mara JO. Fármacos eficaces para el tratamiento de las epilepsias. Hardman JG, Limbrid LE, Molinoff PB, Ruddon RW, Goodman Gilman A. Las bases farmacológicas de la terapéutica. 9º ed. México: McGraw-Hill Interamericana;1996. p. 491-519. 7) Borden Ch. Valproate. Schatzberg AF, Nemeroff ChB. Textbook of Psychopharmacology. 3º ed. Washington DC: American Psychiatric Publishing; 2004. p. 567-79. 8) Ketter TA, Wang Po W, Post RM. Carbamazepine and Oxcarbazepine. Schatzberg AF, Nemeroff ChB. Textbook of Psychopharmacology. 3º ed. Washington DC: American Psychiatric Publishing;2004. p. 581-606. 9) Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999;4:117-28. 10) Alvano SA. Perspectiva Neurocientífica. Mediciencia s.a ed. Avatares de la Clínica. Buenos Aires: Masson Doyma;2004. p. 25-123. 11) Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541-7. 12) Strakowski SM, Adler CM, DelBello MP. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord 2002;4:80-88. 13) Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-136. 14) Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411-9. 15) Marcus R, Coulston AM. Las vitaminas. Goodman Gilman A, Rall TW, Nies AS, Taylor P. Las bases farmacológicas de la terapéutica. 8º ed. México: Editorial Médica Panamericana;1991. p. 1471-77. 16) Zorrilla Zubilete M. Caminos intracelulares de comunicación neuronal vinculados a la familia de proteínas Wnt y su relación con el mecanismo de acción del litio y la enfermedad de Alzheimer. Psicofarmacología 2000;7:8-11. 17) Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002;7:846-56. 18) Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentation by muscarinic receptor activation. J Neurochem 1996;67:767-77. 19) Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000;75: 1729-34. 20) Swierczynski SL, Blackshear PJ. Myristoylation -dependent and electrostatic interactions exert independent effects on the membrane association of the myristoylated alanine-rich protein kinase C substrate protein in intact cells. J Biol Chem 1996;271:3424-30. 21) Meijer L, Flajolet M and Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004;25:471-80. 22) Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist 2002;8:497-511. 23) Zou Y. Wnt signaling in axon guidance. Trends Neurosci 2004;27:528-32. 24) Williams RS, Cheng L, Mudge AW, Harwood A. A common mechanism of action for three moodstabilizing drugs. Nature 2002;417:292-5. 25) Jufé G, Mazaira S, Zorrilla M. Farmacología del litio. Zieher LM, Alvano SA, Fadel D, Iannantuno R, Serra A, editores. Psiconeurofarmacología clínica y sus bases neurocientíficas. 3º ed. Buenos Aires: Siltor;2003. p. 391-7. 26) Pap M, Cooper GM. Role of glycogen synthase kinase - 3 in the phosphatidylinositol 3- kinase/Akt cell survival pathway. J Biol Chem 1998;273:929-32. 27) Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3 , mood stabilizers, and neuroprotection. Bipolar Disord 2002;4:137-44.

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015